Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) today announces it has successfully initiated the first explorative human clinical study (OX640-001) for OX640, an adrenaline rescue medication with nasal delivery. The study aims to determine the relative bioavailability and absorption ...
Faeth Therapeutics, a cancer metabolism company, today announced the closing of a $47 million Series A round of private financing led by S2G Ventures, bringing total funding to date to $67 million. The proceeds of the financing will ...
PreventionGenetics, a subsidiary of Exact Sciences Corp., announced today that it was recently granted marketing authorization for the POMC/PCSK1/LEPR companion diagnostic (CDx) genetic test as a Class II device by the Center for Devices and Radiological ...
Popular Posts
